178 related articles for article (PubMed ID: 34302463)
1. Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T.
Hawley JE; Pan S; Kandadi H; Chaimowitz MG; Sheikh N; Drake CG
J Natl Cancer Inst; 2022 Feb; 114(2):314-317. PubMed ID: 34302463
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
3. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG
Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218
[No Abstract] [Full Text] [Related]
4. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
[TBL] [Abstract][Full Text] [Related]
5. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
[TBL] [Abstract][Full Text] [Related]
7. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract][Full Text] [Related]
8. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
[TBL] [Abstract][Full Text] [Related]
10. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
[TBL] [Abstract][Full Text] [Related]
11. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
13. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
14. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
Marshall CH; Fu W; Wang H; Park JC; DeWeese TL; Tran PT; Song DY; King S; Afful M; Hurrelbrink J; Manogue C; Cotogno P; Moldawer NP; Barata PC; Drake CG; Posadas EM; Armstrong AJ; Sartor O; Antonarakis ES
Clin Cancer Res; 2021 Mar; 27(6):1623-1630. PubMed ID: 33451978
[TBL] [Abstract][Full Text] [Related]
16. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
17. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.
McKay RR; Hafron JM; Ferro C; Wilfehrt HM; Fitch K; Flanders SC; Fabrizio MD; Schweizer MT
Adv Ther; 2020 Dec; 37(12):4910-4929. PubMed ID: 33029725
[TBL] [Abstract][Full Text] [Related]
18. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
Plosker GL
Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
[TBL] [Abstract][Full Text] [Related]
20. Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
Zhang L; Kandadi H; Yang H; Cham J; He T; Oh DY; Sheikh NA; Fong L
Cancer Immunol Res; 2020 Dec; 8(12):1496-1507. PubMed ID: 32967912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]